UNSPSC 51341600: Antiviral adamantanes

Antiviral drugs made from a bridged compound and a cycloalkane (C10H16).

UNSPSC 51341600 Antiviral adamantanes, a Class code, shows minimal recent state and local activity directly aligned with its nominal scope. The recent opportunities tagged under this code diverge substantially from antiviral adamantane pharmaceuticals; instead, they encompass naloxone procurement, direct-to-manufacturer prescription program planning, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals through cooperative purchasing. State and local governments are soliciting these products through varied issuing bodies—county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal fire departments and purchasing offices (City of Tampa), and state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The geographic spread spans Florida, Texas, Minnesota, and Oregon, with activity concentrated among county health systems and state-level procurement offices managing pharmaceuticals and emergency medical supplies at scale.

Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (response deadline July 26, 2023), the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 and a response deadline of March 13, 2026, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal deadline. The Texas HHS Commission also issued an RFI in April 2026 exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The code appears to be receiving misdirected opportunity tags; no solicitations in the recent block actually seek antiviral adamantane products specifically, making pursuit decisions here dependent on whether your firm competes in the broader emergency medical supply and pharmaceutical distribution space rather than the antiviral segment the code nominally describes.